More articles from Endocrine/Neuroendocrine Cancers

You have access
Real-World Lesion and Renal Dosimetry for Peptide Receptor Radionuclide Therapy (PRRT)
Price Jackson, Ramin Alipour, Rodney Hicks, Lachlan McIntosh, Jason Callahan and Grace Kong

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2210;
You have access
Prospective phase II trial of prognostication by [68Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT for integrin alpha v beta 3 imaging in patients with neuroendocrine neoplasms
Esben Carlsen, Mathias Loft, Annika Loft, Dorota Czyzewska, Seppo Langer, Ulrich Knigge and Andreas Kjaer

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2209;
You have access
A Phase II clinical study on 225Ac-DOTATATE Therapy in Advanced Stage Gastroenteropancreatic Neuroendocrine Tumor Patients
Chandrasekhar Bal, Sanjana Ballal and Madhav Yadav

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2208;
You have access
The kinetic analysis of the somatostatin receptor antagonist [18F]AlF-NOTA-JR11 in liver metastases of neuroendocrine tumors
Xiangxi Meng, Jiangyuan Yu, Qing Xie, Hanjing Kong and 志杨

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2212;
You have access
Restoration of Radioiodine Uptake in Radioiodine-Refractory Thyroid Cancer by MAPK/BRAF Inhibition: The Single-Center Prospective Two-Arm ERRITI Trial
David Kersting, Manuel Weber, Burkhard Riemann, Tim Brandenburg, UDE / Führer, Frank Grünwald, Michael Kreissl, Henning Dralle, Fank Weber, Kurt Schmid, Ina Binse, Ken Herrmann, Walter Jentzen, Hong Grafe, Christoph Rischpler, Sarah Theurer, Andreas Andreas Bockisch, James Nagarajah and Wolfgang Fendler

Journal of Nuclear Medicine August 1, 2022, 63 (supplement 2) 2201;

Main menu

User menu

Search

More articles from Endocrine/Neuroendocrine Cancers

Pages